Want to see YDES full AI Analyst Report?
YDES Stock Chart & Stats
$4.69
--
Market closed
$4.69
--
Day’s Range― - ―
52-Week Range$1.70 - $25.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)91.42K
Market Cap
$332.20M
Enterprise Value$172.49M
Total Cash (Recent Filing)$6.31K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding70,831,345
10 Day Avg. Volume96,756
30 Day Avg. Volume91,419
Financial Highlights & Ratios
PEG Ratio1.29
Price to Book (P/B)-284.80
Price to Sales (P/S)1362.74
P/FCF Ratio-101.20
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-57.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Reported DebtVery low reported debt reduces refinancing and interest-burden risk, preserving some financial flexibility. This is a durable balance-sheet advantage, although it does not offset the company’s negative equity and funding dependence.
Physician-Led Product ExpansionThe Taiwan launch adds consumer-health products, clinician-backed distribution, and a potential recurring-revenue channel. Its stated capital-light partnership model could strengthen customer trust and create cross-selling links to diagnostics and clinical services.
Revenue Base EstablishedHaving an established revenue base and strong 2024 growth provides evidence of market demand and a platform for scaling. However, revenue remains small, so sustained growth and improved operating leverage are needed to make this durable.
Bears Say
Negative EquityNegative equity signals substantial balance-sheet strain and reduces financial resilience. It may require recapitalization or equity issuance, creating dilution risk and limiting the company’s ability to fund operations without external capital.
Persistent Cash BurnPersistent and accelerating cash outflows show limited self-funding capacity. Continued reliance on external financing raises liquidity risk and could constrain investment in products, partnerships, and regulated healthcare initiatives if funding access weakens.
Deteriorating ProfitabilityThe shift from modest profitability in 2023 to significant losses in 2024–2025 indicates weak earnings quality and limited operating leverage. Negative gross profit also suggests cost pressure or elevated spending that may persist until scale improves.
YD Bio Limited News
YDES FAQ
What was YD Bio Limited’s price range in the past 12 months?
YD Bio Limited lowest stock price was $1.70 and its highest was $25.00 in the past 12 months.
What is YD Bio Limited’s market cap?
YD Bio Limited’s market cap is $332.20M.
When is YD Bio Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were YD Bio Limited’s earnings last quarter?
Currently, no data Available
Is YD Bio Limited overvalued?
According to Wall Street analysts YD Bio Limited’s price is currently Overvalued.
Does YD Bio Limited pay dividends?
YD Bio Limited does not currently pay dividends.
What is YD Bio Limited’s EPS estimate?
YD Bio Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does YD Bio Limited have?
YD Bio Limited has 70,831,345 shares outstanding.
What happened to YD Bio Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of YD Bio Limited?
Currently, no hedge funds are holding shares in YDES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
YD Bio Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
YD Bio Limited
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Scinai Immunotherapeutics
―
Aditxt
―
SciSparc Ltd.
―
CDT Equity
―
Virax Biolabs Group Ltd. Class A
―
Ownership Overview
0.09% Insiders
0.06% Mutual Funds
0.17% Other Institutional Investors
99.65% Public Companies and
Individual Investors